Tsimberidou, A. M., Dayyani, F., Sommerhalder, D., Vandross, A. L., Pelster, M., Perez, C. A., Chandhasin, C., Dai, Y., Tu, S., King, I., Perabo, F. (2025). Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3124